A significant proportion of patients with chronic myeloid leukemia and suboptimal response according to European Leukemia Net criteria have excellent prognosis without treatment change
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F13%3A33142572" target="_blank" >RIV/61989592:15110/13:33142572 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00098892:_____/13:#0000464
Výsledek na webu
<a href="http://dx.doi.org/10.5507/bp.2011.059" target="_blank" >http://dx.doi.org/10.5507/bp.2011.059</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.5507/bp.2011.059" target="_blank" >10.5507/bp.2011.059</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
A significant proportion of patients with chronic myeloid leukemia and suboptimal response according to European Leukemia Net criteria have excellent prognosis without treatment change
Popis výsledku v původním jazyce
Background. The Recommendations of the European Leukemia Net (ELN) have become an essential tool in the management and prognosis of patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs). However, the definition of suboptimal response remains under discussion. Methods. We used conventional cytogenetics for the detection of clonal changes in Ph-positive and negative clones. RT-PCR and sequencing were carried out on peripheral blood leukocytes to detect the type of BCR-ABL1 transcript. The BCR-ABL1 mutational status was assessed using sequencing of RT-PCR products. High performance capillary electrophoresis for determination of imatinib (IMA) plasma concentration was used. Results. A retrospective study of 110 patients diagnosed with chronic-phase (CP) CML treated with IMA or 2nd generation TKIs in the years 2000-2009 focused on analysis of patients with suboptimal response according to ELN criteria. 40 patients were administered IMA as first-line the
Název v anglickém jazyce
A significant proportion of patients with chronic myeloid leukemia and suboptimal response according to European Leukemia Net criteria have excellent prognosis without treatment change
Popis výsledku anglicky
Background. The Recommendations of the European Leukemia Net (ELN) have become an essential tool in the management and prognosis of patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs). However, the definition of suboptimal response remains under discussion. Methods. We used conventional cytogenetics for the detection of clonal changes in Ph-positive and negative clones. RT-PCR and sequencing were carried out on peripheral blood leukocytes to detect the type of BCR-ABL1 transcript. The BCR-ABL1 mutational status was assessed using sequencing of RT-PCR products. High performance capillary electrophoresis for determination of imatinib (IMA) plasma concentration was used. Results. A retrospective study of 110 patients diagnosed with chronic-phase (CP) CML treated with IMA or 2nd generation TKIs in the years 2000-2009 focused on analysis of patients with suboptimal response according to ELN criteria. 40 patients were administered IMA as first-line the
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
<a href="/cs/project/NT12218" target="_blank" >NT12218: Individualizovaná léčba chronických myeloproliferativních stavů a myelodysplastického syndromu - studie buněčné metabolomiky</a><br>
Návaznosti
S - Specificky vyzkum na vysokych skolach
Ostatní
Rok uplatnění
2013
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Biomedical Papers-Olomouc
ISSN
1213-8118
e-ISSN
—
Svazek periodika
157
Číslo periodika v rámci svazku
2
Stát vydavatele periodika
CZ - Česká republika
Počet stran výsledku
8
Strana od-do
181-188
Kód UT WoS článku
—
EID výsledku v databázi Scopus
—